Jan. 9, 2025 — Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond, according to new research published  in Hypertension, a peer-reviewed journal of the American Heart Association.

Jan. 13, 2025 — Medtronic plc recently announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk of stroke, atrial fibrillation and heart failure, while current pipe use was associated with increased risk of heart failure. Users of smokeless tobacco products had increased risk for myocardial infarction and mortality due to coronary heart disease.

Jan. 13, 2025 – R3 Vascular Inc., a medical device company dedicated to treating peripheral arterial disease (PAD), recently announce it received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDEÒ Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD). 

A new study reports persistent disparities in outcomes for people with peripheral artery disease (PAD) and its more severe form, chronic limb-threatening ischemia (CLTI) in the United States.

Jan. 13, 2025 -- ERS Genomics, the CRISPR licensing company, has announced the launch of its Express License platform to provide small research enterprises and startups with affordable and rapid access to the world’s largest foundational and essential CRISPR/Cas9 patent portfolio.

Jan. 8, 2025 — Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for a Phase 2 clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apnea (OSA) and hypertension. The Company anticipates initiating the trial in the first quarter of 2025.

Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) and has been accepted into the FDA’s Total Product Lifecycle Advisory Program (TAP). 

FIRE1’s Norm heart failure management system offers a unique approach for patients to manage heart failure. By enabling patients to engage in physician directed self-management, Norm reduces the burden on healthcare staff, making it easier to keep patients healthier and at home.

Jan. 6, 2025 — Medtronic plc has announced it received CE (Conformité Européenne) Mark for the Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT). The Harmony TPV system has already been implanted in more than 2,200 patients and now has access to help many more patients across the European Union.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now